Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a double-blind placebo-controlled 2-period crossover study to evaluate the safety and efficacy of BCX4161 as a prophylactic treatment to reduce the frequency of attacks in subjects with hereditary angioedema

Trial Profile

A Phase 2a double-blind placebo-controlled 2-period crossover study to evaluate the safety and efficacy of BCX4161 as a prophylactic treatment to reduce the frequency of attacks in subjects with hereditary angioedema

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avoralstat (Primary)
  • Indications Hereditary angioedema
  • Focus Proof of concept; Therapeutic Use
  • Acronyms OPuS-1
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 07 Oct 2014 According to a BioCryst Pharmaceuticals media release, results will be presented at the 23rd EADV Congress.
    • 15 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 May 2014 Results published in the BioCryst media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top